AEON fails an­oth­er mi­graine tri­al, shares halve as com­pa­ny re­views op­tions

AEON Bio­phar­ma said its bot­u­linum tox­in treat­ment can­di­date failed a Phase 2 mi­graine study at the planned in­ter­im analy­sis. The com­pa­ny’s share price $AEON was halved in pre­mar­ket trad­ing on Fri­day.

An “un­ex­pect­ed place­bo ef­fect” spelled trou­ble for the tri­al. The com­pa­ny said it will eval­u­ate next steps for de­vel­op­ing ABP-450 and has “im­me­di­ate­ly com­menced cash preser­va­tion mea­sures and will re­view all strate­gic op­tions.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER